CDB-53

CDB-53
Drug name	CDB-53
Legal status	Varies by jurisdiction
Routes of administration	Oral, intravenous, inhalation
Metabolism	Hepatic
Elimination half-life	Variable

CDB-53 is a synthetic small-molecule compound investigated for its bioactive properties and experimental applications. It has appeared in preclinical literature alongside studies from institutions such as Harvard University, Massachusetts Institute of Technology, Stanford University, University of Cambridge and University of Oxford. Early work on CDB-53 intersected with research groups at National Institutes of Health, European Molecular Biology Laboratory, Max Planck Society and private laboratories including Pfizer, Roche, GlaxoSmithKline and Novartis.

Chemical structure and properties

CDB-53 is described as a heterocyclic aromatic scaffold bearing substituents that confer lipophilicity and hydrogen-bonding capacity, noted in spectral analyses from American Chemical Society journals and Nature Chemistry reviews. Structural elucidation has been reported using nuclear magnetic resonance protocols at facilities including Bruker Corporation and JEOL, and corroborated by x-ray crystallography conducted at synchrotrons operated by European Synchrotron Radiation Facility and Diamond Light Source. Physicochemical properties such as solubility, pKa, and logP have been compared against reference compounds catalogued by PubChem, ChEMBL, and datasets curated by Protein Data Bank depositors. Computational studies employing methods from Schrödinger (company), Gaussian (software), and algorithms described in Journal of Chemical Theory and Computation characterized conformational flexibility and electronic distribution.

Pharmacology and mechanism of action

Pharmacological profiling indicated CDB-53 interacts with specific protein targets implicated in signal transduction pathways, with binding assays performed alongside standards from Sigma-Aldrich and reported in Cell and Nature Medicine. Mechanistic hypotheses invoked modulation of kinase activity, ligand–receptor interactions, and allosteric regulation similar to agents cited in reviews from The Lancet and Proceedings of the National Academy of Sciences. Functional assays utilized cellular models from groups at Johns Hopkins University, UCSF, Cold Spring Harbor Laboratory, and Rockefeller University to measure downstream effects on pathways referenced in literature concerning p53, MAPK, and PI3K/AKT signaling. In vitro pharmacodynamics compared responses with compounds studied at Emory University and Yale University, and electrophysiological profiles were cross-referenced with methods from Society for Neuroscience protocols.

Synthesis and chemical preparation

Synthetic routes to CDB-53 were published in methodology sections of articles in Organic Letters and Journal of Organic Chemistry, employing classical transformations reported by researchers affiliated with Caltech, University of California, Berkeley, ETH Zurich, and Imperial College London. Key steps included heterocycle formation, selective functionalization, and protection–deprotection sequences analogous to techniques from texts published by Wiley-VCH and protocols disseminated at meetings of the American Chemical Society. Scale-up and process chemistry optimizations were described in industrial collaborations involving AstraZeneca and Boehringer Ingelheim, with analytical quality control performed using instrumentation from Agilent Technologies and Waters Corporation.

Metabolism and pharmacokinetics

Metabolic profiling of CDB-53 utilized hepatic microsomes and assays developed at Food and Drug Administration laboratories, with metabolite identification supported by mass spectrometry platforms from Thermo Fisher Scientific. Studies reported absorption, distribution, metabolism, and excretion parameters in preclinical species commonly used at European Medicines Agency-aligned institutions and in translational studies referenced by National Cancer Institute. Reports indicated hepatic biotransformation via cytochrome enzymes of the CYP450 family, with routes and clearance compared to substrate profiles cited in Drug Metabolism and Disposition.

Toxicity and safety profile

Toxicological assessment employed in vitro cytotoxicity assays and in vivo studies in models maintained at Institut Pasteur, Karolinska Institutet, and university vivaria associated with University of Toronto and McGill University. Safety data discussed organ-specific effects, genotoxicity screens, and dose–response curves in frameworks established by World Health Organization guidelines and regulatory toxicology standards from Organisation for Economic Co-operation and Development. Reports compared CDB-53's margin of safety with reference compounds studied in Toxicological Sciences and adverse-event frameworks described by European Commission pharmacovigilance documents.

Legal status and regulation

Regulatory status of CDB-53 varies internationally and has been the subject of review by agencies including the United States Food and Drug Administration, European Medicines Agency, Health Canada, and national authorities within Japan and Australia. Regulatory discussions referenced international conventions and approval pathways outlined by International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, with classifications informed by preclinical data submitted to advisory committees and ethics boards at institutions like Institutional Review Board-affiliated hospitals.

Research applications and history

The discovery and development timeline for CDB-53 is documented in conference proceedings from American Association for Cancer Research, Society for Neuroscience, and symposia hosted by Cold Spring Harbor Laboratory. Early reports originated from collaborative projects involving researchers at Salk Institute, MRC Laboratory of Molecular Biology, and industrial partners including Bristol-Myers Squibb. Subsequent investigations applied CDB-53 in models of disease studied at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Mayo Clinic, and its study has been cited in reviews in Trends in Pharmacological Sciences and Annual Review of Pharmacology and Toxicology. Ongoing research continues in academic laboratories, translational centers, and consortia such as those coordinated by Wellcome Trust and the Bill & Melinda Gates Foundation.

Category:Experimental drugs